A venture capital syndicate led by Netherlands-based Life Sciences Partners (LSP) is providing $180 million to Arvelle Therapeutics GmbH, a recently created Swiss company, which has exclusive rights to develop and commercialise a new epilepsy drug in Europe.
The Series A funding is reportedly one of the largest rounds of its kind for a European-focused biopharmaceutical company. Besides LSP, the syndicate includes Andera Partners, NovaQuest Capital Management, BRV Capital Management and H.I.G. BioHealth Partners.